Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma

Category	Detail
Condition	Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS)
Key Mechanisms
Target Population
Care Setting

IM3OS is a severe immune-related adverse event associated with immune checkpoint inhibitors.
Symptoms include weakness, ptosis, dysarthria, and myalgias.
Flow cytometry identified expanded memory CD8+ T-cell populations during disease flare.
Successful treatment included high-dose glucocorticoids, mycophenolate mofetil, and intravenous immunoglobulin.
Mortality rate for IM3OS can be approximately 60%.
Rapid symptom progression can lead to severe outcomes.

Diagnosis can be challenging due to atypical presentation and lack of classical autoimmune markers.
Consider specific diagnostic tests such as serum creatine kinase and autoantibody panels.

Treatment response can vary; monitoring immune cell subsets may provide insights into disease activity, with examples of variability in response.

Utilize flow cytometry to assess immune cell populations in patients with suspected IM3OS.
Consider early intervention with glucocorticoids for symptomatic management.
Implement regular monitoring of vital signs and symptom progression.

Clinical Scorecard: Case Study: Overlap Syndrome of Myocarditis, Myositis, and Myasthenia Gravis Linked to Immune Checkpoint Inhibitors with Flow Cytometric Analysis Before and After Therapy in a Urothelial Carcinoma Patient